Ruth Riisnaes

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Joaquı́n Mateo, Suzanne Carreira, Shahneen Sandhu et al. · New England Journal of Medicine · 2015 · 2.2K citations · Full text

Medicine, Molecular Biology, Oncology +17

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

Joaquı́n Mateo, Núria Porta, Diletta Bianchini et al. · The Lancet Oncology · 2019 · 644 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

Shahneen Sandhu, William R. Schelman, George Wilding et al. · The Lancet Oncology · 2013 · 558 citations

Medicine, Oncology, Pharmacology +12

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

Timothy A. Yap, Yan Li, Amita Patnaik et al. · Journal of Clinical Oncology · 2011 · 543 citations

Medicine, Oncology, Pharmacology +17

Characterization of <i>ERG</i> , <i>AR</i> and <i>PTEN</i> Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer

Gerhardt Attard, Joost F. Swennenhuis, David Olmos et al. · Cancer Research · 2009 · 532 citations · Full text

Medicine, Oncology, Pharmacology +17